MELBOURNE, Australia--(BUSINESS WIRE)--Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company has been awarded a product development grant for its Cancer-related Alimentary Mucositis project. The award was one of only three made by the VISTECH bi-national fund, following a competitive process, which included a thorough scientific assessment. The fund was established by the Government of Victoria (Australia) and the Government of Israel through the Office of the Chief Scientist in its Ministry of Industry Trade and Labor. The intended product for the oncology market will leverage a special formulation of Anadis’ immune milk-derived anti LPS antibodies, growth factors and other bioactives delivered using Anadis’ oral delivery technology.
